



Supra Alpert Siegel, Ph.D.  
Sparkman, LLP  
1320 W Salmon Street, Suite 1600  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Application No.: 09/617,178  
Filing Date: July 17, 2000

Our Ref. No. 5673-55696  
First Named Inventor: Effendi et al.  
For: VIRAL PROTEIN BINDING  
COMPOSITIONS AND METHODS

Sheet 1 of 6

RECEIVED  
JAN 10 2003

TECH CENTER 1600/2900

FIG. 1





FIG. 2





Susan Albert Siegel, Ph.D.  
Klarq Markman, LLP  
1600 Commercial Street, Suite 1600  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Application No.: 09/617,178  
Filing Date: July 17, 2000

Our Ref. No. 5673-55696  
First Named Inventor: Efsth  
For: VIRAL PROTEIN  
COMPOSITIONS AND METHODS

Sheet 2 of 6


TECH CENTER 1600/2900

JAN 10 2003

RECEIVED

APPROVED BY DRAFTSMAN	O.G. FIG.	
	CLASS	SUBCLASS

FIG. 3





Susan Alpert Siegel, Ph.D.  
Quist Sparkman, LLP  
1600 W Salmon Street, Suite 1600  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Application No.: 09/617,178  
Filing Date: July 17, 2000

Our Ref. No. 5673-55696  
First Named Inventor: E. J. You et al.  
For: VIRAL PROTEIN BINDING  
COMPOSITIONS AND METHODS

Sheet 3 of 6

TECH CENTER 1600/2900


JAN 10 2003

RECEIVED

O.G. FIG.	
APPROVED	BY
DRAFTSMAN	
SUBCLASS	

FIG. 4a


MIP-1 $\alpha$



M3 inhibits binding of MIP-1 $\alpha$  to their natural receptors expressed on U937 cells.

FIG. 4b

IL-8



M3 inhibits binding of IL-8 to their natural receptors expressed on U937 cells.



Susan Alpert Siegel, Ph.D.  
Klauss Sparkman, LLP  
1000 Salmon Street, Suite 1600  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Application No.: 09/617,178  
Filing Date: July 17, 2000


Our Ref. No. 5673-55696  
First Named Inventor: Efstatios et al.  
For: VIRAL PROTEIN INHIBITORS  
COMPOSITIONS AND METHODS

Sheet 4 of 6

RECEIVED  
JAN 10 2003  
TECH CENTER 1600/2900


APPROVED BY DRAFTSMAN	O.G. FIG.	SUBCLASS
	CLASS	

FIG. 5



Heparin and heparin sulfate do not interfere with the capacity for M3 to bind to radio-labeled IL-8 or MIP-1 $\alpha$ .

FIG. 6



M3 inhibits RANTES induced Ca<sup>2+</sup> flux in human PBMCs in a dose dependent manner.



Susan Albert Siegel, Ph.D.  
Klarman Parkman, LLP  
2500 Commonwealth Street, Suite 1600  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Application No.: 09/617,178  
Filing Date: July 17, 2000


Our Ref. No. 5673-55696  
First Named Inventor: Efsthathiou, et al.  
For: VIRAL PROTEIN COMPOSITIONS AND METHODS

Sheet 5 of 6

RECEIVED  
JAN 10 2003  
TECH CENTER 1600/2900


APPROVED BY DRAFTSMAN		O.G. FIG.	
		CLASS	SUBCLASS

FIG. 7a



M3 inhibits MCP-1 induced migration of THP-1 cells in a dose dependent manner.

FIG. 7b



M3 inhibits IL-8 induced migration of neutrophils in a dose dependent manner.



Susan Alpert Siegel, Ph.D.  
K. Sparkman, LLP  
2000 Salmon Street, Suite 1600  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Application No.: 09/617,178  
Filing Date: July 17, 2000

Our Ref. No. 5673-55696  
First Named Inventor: Efstathiou et al.  
For: VIRAL PROTEIN COMPOSITIONS AND METHODS

Sheet 6 of 6


TECH CENTER 1600/2900

JAN 10 2003

RECEIVED

APPROVED	O.G. FIG.	SUBCLASS
BY	CLASS	
DRAFTSMAN		

FIG. 8



Effect of M3 on contact sensitivity inflammatory response in mice.

Values represent mean difference in ear-thickness between control and challenged ears  $\pm$  SD. Statistical analysis was performed between M3 treated groups (10 and 100μg/injection) and the ovalbumin (Pva) control group (100μg/injection) using Student's T-test (\*p<0.05).